Browsing: The Regeneron Paradox: Deep Value or Value Trap After the Itepekimab Crash?

Introduction: A Biotech Behemoth at a Crossroads Regeneron Pharmaceuticals (REGN), once a darling of the biotech sector, finds itself navigating turbulent waters. Following a devastating 19%…